KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Biology / 2020 / Cilt: 44 - Sayı: 6

Oncogenic and tumor suppressor function of MEIS and associated factors

Birkan GİRGİN
Medine KARADAĞ-ALPASLAN
Fatih KOCABAŞ
Sayfa
328–355
Yayın Tarihi
2020-12-14
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer.
📊
Temel Bulgular & Veri:MEIS and associated PBX-HOX proteins may act as tumor suppressors or oncogenes in different cellular settings.
💡
Sonuç & Katkı:Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:MEIS · cancer · small molecules

Abstract

MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer. MEIS and associated PBX-HOX proteins may act as tumor suppressors or oncogenes in different cellular settings. Their expressions tend to be misregulated in various cancers. Bioinformatic analyses have suggested their upregulation in leukemia/lymphoma, thymoma, pancreas, glioma, and glioblastoma, and downregulation in cervical, uterine, rectum, and colon cancers. However, every cancer type includes, at least, a subtype with high MEIS expression. In addition, studies have highlighted that MEIS proteins and associated factors may function as diagnostic or therapeutic biomarkers for various diseases. Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.

🔖

Bu Makaleye Atıf Yap

GİRGİN, B., KARADAĞ-ALPASLAN, M., KOCABAŞ, F. (2020). Oncogenic and tumor suppressor function of MEIS and associated factors. Turkish Journal of Biology, Cilt: 44 - Sayı: 6, 328–355. https://ajindex.com/articles/197897

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Aamar E, 2004,
  2. DEVELOPMENT, V131, P153, DOI 10.1242/dev.00905 Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907 Abbaszadegan MR, 2018, PATHOL ONCOL RES, V24, P245, DOI 10.1007/s12253-017-0243-1 Agoston Z, 2014,
  3. DEVELOPMENT, V141, P28, DOI 10.1242/dev.097295 Aksoz M, 2018, CURR DRUG TARGETS, V19, P181, DOI 10.2174/1389450118666170724165514 Alvarado-Ruiz Liliana, 2016, Asian Pac J Cancer Prev, V17, P1037 Ando H, 2014, CANCER CHEMOTH PHARM, V73, P53, DOI 10.1007/s00280-013-2316-5 Xavier FCA, 2014, ARCH ORAL BIOL, V59, P783, DOI 10.1016/j.archoralbio.2014.05.001 Argani P, 2018, AM J SURG PATHOL, V42, P1562, DOI 10.1097/PAS.0000000000001140 Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001 Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343 Aulisa L, 2009, ACTA BIOMATER, V5, P842, DOI 10.1016/j.actbio.2008.11.002 Azcoitia V, 2005, DEV BIOL, V280, P307, DOI 10.1016/j.ydbio.2005.01.004 Bach DH, 2018, CANCER LETT, V419, P152, DOI 10.1016/j.canlet.2018.01.053 Bakkum-Gamez JN, 2015, GYNECOL ONCOL, V137, P14, DOI 10.1016/j.ygyno.2015.01.552 Bell A, 2011, CANCER-AM CANCER SOC, V117, P2898, DOI 10.1002/cncr.25818 Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106 Berrondo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147236 Beukers W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077657 Beukers W, 2013, J UROLOGY, V190, P311, DOI 10.1016/j.juro.2013.01.078 Bhanvadia RR, 2018, CLIN CANCER RES, V24, P3668, DOI 10.1158/1078-0432.CCR-17-3673 Bhatlekar S, 2018, J CELL PHYSIOL, V233, P727, DOI 10.1002/jcp.25981 Blasi F, 2017,
  4. BIOESSAYS, V39, DOI 10.1002/bies.201600245 Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799 Calle AS, 2018, CANCER SCI, V109, P2093, DOI 10.1111/cas.13642 Calvo KR, 1999,
  5. ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377 Cantile M, 2003,
  6. ONCOGENE, V22, P6462, DOI 10.1038/sj.onc.1206808 Cantile M, 2013, INT J MOL SCI, V14, P21727, DOI 10.3390/ijms141121727 Care A, 1996, MOL CELL BIOL, V16, P4842. Carninci P, 2007, CURR OPIN GENET DEV, V17, P139, DOI 10.1016/j.gde.2007.02.008 Carrera M, 2015, INT J CLIN EXP PATHO, V8, P3613 CARROLL AJ, 1984,
  7. BLOOD, V63, P721. Chang CJ, 2017, J CANCER, V8, P1071, DOI 10.7150/jca.17295 Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679 Chen FH, 2011, MED ONCOL, V28, P1201, DOI 10.1007/s12032-010-9634-9 Chen GX, 2018, ONCOTARGETS THER, V11, DOI 10.2147/OTT.S152362 Chen JL, 2012, CLIN CANCER